AGIO — Agios Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $2.21bn
- $1.59bn
- $54.03m
Brief: FDA Accepts Agios' Supplemental New Drug Application For Pyrukynd® (Mitapivat)
Brief: FDA Approves Update To USPI For Agios Pharmaceuticals's Pyrukynd For Hemolytic Anemia
Brief: Agios Presents Positive Results From Phase 3 Energize-T Study Of Mitapivat At Ash 2024 And Provides Regulatory Update On Mitapivat
Agios Pharmaceuticals Inc reports results for the quarter ended in January 1 - Earnings Summary
Brief: Agios Reports Business Highlights And Third Quarter 2024 Financial Results
Brief: Agios Pharmaceuticals Q3 Product Revenue USD 8.964 Million
U.S. STOCKS ON THE MOVE-IonQ, Cassava Sciences, MeridianLink
U.S. STOCKS ON THE MOVE-Regeneron, HP Inc, Honeywell International
Agios' drug could have similar outcome as Pfizer's sickle cell treatment, says Leerink
U.S. STOCKS ON THE MOVE-Cassava Sciences, Wave Life Sciences, Bumble
Agios' drug could have similar outcome as Pfizer's sickle cell treatment, says Leerink
U.S. STOCKS ON THE MOVE-Starbucks, Crocs, Accenture
U.S. STOCKS ON THE MOVE-Crocs, First Solar, Qualcomm
Sickle cell drug developers rise after Pfizer withdraws its treatment
US FDA approves Servier's brain tumor treatment
Brief: Agios To Receive $1.1 Billion In Milestone Payments Following FDA Approval Of Vorasidenib
Brief: Agios Pharmaceuticals Q2 Product Revenue USD 8.615 Million
Agios Pharmaceuticals Inc expected to post a loss of $1.60 a share - Earnings Preview
Brief: Agios Presents Positive Results From Phase 3 Energize Study Of Mitapivat